CHRS is a rocket ship via /r/wallstreetbets #stocks #wallstreetbets #investing

CHRS is a rocket ship

Don’t believe me? Look at the chart. Small-cap biotech with healthy balance sheet, 14% short interest and almost zero risk of dilution . $60 million in quarterly sales from neulasta biosimilar. Approved lucentis biosimilar launches in October with edge in quality over lone rival biosimilar. Approved humira biosimilar launches next July. Immunoncology drug tori set for Dec. 23. On-body neulasta device to be launched next year. Several other promising immunoncology drugs in development. In short, I believe the current market cap will be less than 2023 revenue. I have 13,845 shares and am holding long term.

Submitted August 05, 2022 at 10:01PM by jixxer1112
via reddit